Recursion Pharmaceuticals stock
RXRXNASDAQRecursion Pharmaceuticals, Inc., HealthcareISIN US75629V1044
36Score 36 out of 100, Weak
Price and trend
54 / 100
Price history
−28% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 4.4% below it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 43).
The price is 33% below its 52-week high. Largest decline in 6 years: 93% (July 2021 to March 2026).
Chart figures for advanced users
- SMA 50$3.79
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.48
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)43
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$2.84
- The lowest closing price of the last twelve months.
- Resistance$4.96
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Recursion Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $2.07B, is number 127 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $74.68M (up 26.9% year on year) and a loss of $644.76M.
- For fiscal 2026, analysts expect on average revenue of $38.95M (down 47.8%) and adjusted earnings per share of −$0.88.
Show more
- MEQIRI Score 36 out of 100 (Weak): rank 598 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 79.9% a year since 2020, Biotechnology median 19.4%.Growth 70
- More cash than debtCash $549.85M, financial debt $74.7M.Stability 53
Weaknesses
- DilutionShare count up 170% since 2020.Capital allocation 18
- Loss-makingLoss of $475.67M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$314.48M over the last 12 months.Fundamentals 17
Its standout strength is growth, while fundamentals and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 39 to 36.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 56.7% on the twelve months before. Up to 2020 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 79.9% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross −62%, operating −868%, net −863%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 103 days
- Last reported
- 2 Nov 2026EPS reported −$0.22 (expected −$0.22)in line with expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 8.1% since 15 Oct 2026.
- Earnings per share
- −$0.88+2.6%
- Revenue
- $38.95M−5.4%
- Earnings per share
- −$0.83+8.1%
- Revenue
- $43.95M−19.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −3.9%Only the cost guidance was lowered: 2026 cash operating expenses now $375 million, with no other change to the outlook.
“We are demonstrating this today by lowering our 2026 full year cash operating expense guidance to $375 million. In total, our revised 2026 guidance represents a nearly 40% reduction from comparable 2024 pro forma expenses.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $1.45M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Borgeson BlakeSale
3 Nov 2026, Board
- Shares
- 40,000
- Price
- $3.88
- Value
- $155,200
- Borgeson BlakeSale
6 Oct 2026, Board
- Shares
- 50,000
- Price
- $4.84
- Value
- $242,000
- Hershberg RobertSale
6 Oct 2026, Board
- Shares
- 25,000
- Price
- $5.00
- Value
- $125,000
Show 10 more
- Khan NajatSale
8 Sept 2026, CEO and President
- Shares
- 22,408
- Price
- $3.52
- Value
- $78,822
- Borgeson BlakeSale
1 Sept 2026, Board
- Shares
- 30,000
- Price
- $3.34
- Value
- $100,200
- Borgeson BlakeSale
4 Aug 2026, Board
- Shares
- 30,000
- Price
- $3.25
- Value
- $97,500
- Borgeson BlakeSale
7 Jul 2026, Board
- Shares
- 40,000
- Price
- $3.96
- Value
- $158,500
- Bumpus NamandjeSale
18 Jun 2026, Board
- Shares
- 3,963
- Price
- $3.18
- Value
- $12,602
- Gibson ChristopherSale
5 Jun 2026, Board
- Shares
- 40,000
- Price
- $3.62
- Value
- $144,800
- Khan NajatSale
5 Jun 2026, CEO and President
- Shares
- 23,588
- Price
- $3.58
- Value
- $84,459
- Bumpus NamandjeSale
3 Jun 2026, Board
- Shares
- 4,386
- Price
- $3.54
- Value
- $15,526
- Borgeson BlakeSale
2 Jun 2026, Board
- Shares
- 30,000
- Price
- $3.68
- Value
- $110,400
- Gibson ChristopherSale
22 May 2026, Board
- Shares
- 40,000
- Price
- $3.08
- Value
- $123,200
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Recursion Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 36
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Aurinia PharmaceuticalsAUPH $2.17B69
- BiohavenBHVN $2.13B42
- Vera TherapeuticsVERA $2.1B35
- Vir BiotechnologyVIR $2.08B52
- First Tracks BiotherapeuticsTRAX $2.05B48
- SepternaSEPN $1.99B49
- Harmony Biosciences HoldingsHRMY $1.98B72
- BioCryst PharmaceuticalsBCRX $1.98B37
ETFs that hold Recursion Pharmaceuticals
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| WisdomTree Artificial Intelligence UCITS ETF USD AccWTI2 | 2.48% | 0.40% | €1.08B |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.18% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.16% | 0.40% | €813.42M |
Show 5 more
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.12% | 0.35% | €1.25B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.06% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.06% | 0.30% | €4.28B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.54B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €964.08M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Apr 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.